Evidence map›Paper›PMID 41104655›Full record

ArticlemAbs2025

Modular generation of multispecific antibodies using protein trans-splicing.

Jared A Shadish, John D Bagert, Amber N Lee, Kenneth K Sharp, Chunning Yang, Yijia Li, Rui Wang, Seungwook Shin, Alina A Malik, Jia Lin and 3 more

Abstract read
In one paragraph

Article in mAbs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jared A ShadishBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0003-1529-4286
John D BagertBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0001-7768-2853
Amber N LeeBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0000-0002-7793-1669
Kenneth K SharpBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0009-0004-7667-1000
Chunning YangBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0009-0004-8173-0650
Yijia LiBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.ORCID 0009-0000-1945-8095
Rui WangBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Seungwook ShinBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Alina A MalikBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Jia LinBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Fengying HuangBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Wenhai LiuBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.
Yariv MazorBiologics Engineering, R&D, AstraZeneca, Gaithersburg, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multispecific antibodies are exhibiting rapid growth in drug development due to their ability to engage multiple therapeutic targets and deliver unique functional properties inaccessible to conventional monoclonal antibodies. The development of these complex modalities, however, is limited by the large design space created by the numerous possible combinations associated with multiple binding moieties and molecular formats. Here, we present a high-throughput platform for the efficient production and screening of complex combinatorial multispecific antibody libraries using intein-mediated protein splicing. To validate the fidelity of this screening approach, we demonstrate that spliced bispecific molecules exhibit indistinguishable biochemical and functional properties compared to bispecific antibodies generated through conventional production processes. We further demonstrate that intein splicing can be combined with the DuetMab platform to create trispecific antibodies and perform dual-splicing reactions to generate bivalent bispecific and trispecific formats. This work establishes intein-based protein splicing as a powerful strategy for the efficient generation and screening of multispecific antibodies libraries, enabling the rapid identification of optimal binding configurations, combinations, and molecular formats that elicit the desired mechanism of action.

Indexed as

Antibodies, BispecificAntibodies, MonoclonalProtein EngineeringProtein SplicingTrans-SplicingAnimalsHumansInteinsAntibodies, BispecificAntibodies, MonoclonalbispecificcombinatorialDuetMabhigh-throughputinteinMultispecific

Identifiers

PMID41104655
PMCPMC12536634

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.